Trifluoperazine 1mg/5ml oral solution sugar free

Land: Storbritannien

Språk: engelska

Källa: MHRA (Medicines & Healthcare Products Regulatory Agency)

Aktiva substanser:

Trifluoperazine hydrochloride

Tillgänglig från:

Advanz Pharma

ATC-kod:

N05AB06

INN (International namn):

Trifluoperazine hydrochloride

Dos:

200microgram/1ml

Läkemedelsform:

Oral solution

Administreringssätt:

Oral

Klass:

No Controlled Drug Status

Receptbelagda typ:

Valid as a prescribable product

Produktsammanfattning:

BNF: 04020100; GTIN: 5021691019619

Bipacksedel

• Rarely
patients
may
develop
Neuroleptic
Malignant
Syndrome.
This
causes a high temperature, rigid muscles, drowsiness, occasional loss
of
consciousness,
and
requires
emergency
admission
to
hospital
for
treatment.
• If you have chest pain (angina) and your pain is getting worse.
• Very occasionally, medicines such as Trifluoperazine 1mg/5ml Syrup
can
have effects on muscle control. If this happens, symptoms can include
slurred speech, odd movements of the face, particularly of the tongue,
eyes, head or neck (such as twisting of the neck which causes an
unnatural positioning of the head, rigid muscles, tremors or
restlessness
and difficulty in sitting still). Some patients (especially on high
doses of
this medicine) experience problems with muscle control which may
continue for years. Such patients may experience constant chewing or
tongue movements or other gentle movements of the neck, head or trunk.
Uncontrollable movements of the arms and legs have also been reported
in these patients.
• Occasionally, some patients have complained of feeling slowed
down,
whilst
• Rarely, jaundice (yellowing of skin and whites of eyes), eye
problems,
skin colouring (pigmentation) and blood problems.
• if you suffer from a sore throat, high fever, feel very tired,
become pale,
develop bruises and nose bleeds. These may indicate blood problems
developing as a result of using this medicine.
• In elderly people with dementia, a small increase in the number of
deaths
has been reported for patients taking antipsychotics compared with
those
not receiving antipsychotics.
Some
patients
may
also
experience
weakness,
drowsiness,
dizziness,
restlessness,
difficulty
in
sleeping,
dry
mouth,
blurred
vision,
muscle
weakness, loss of appetite, faintness on standing up, skin rashes
(including
increased sensitivity to the sun), weight gain, water retention
causing
swelling or confusion.
Your
doctor
should
check
your
progress
regularly
if
you
are
on
Trifluoperazine 1mg/5ml Syrup to make sure no unwanted effects are
developing.
If an

Produktens egenskaper

OBJECT 1
TRIFLUOPERAZINE 1MG/5ML SYRUP
Summary of Product Characteristics Updated 24-Apr-2014 | Concordia
International - formerly AMCo
1. Name of the medicinal product
Stelazine 1mg/5ml Syrup
Trifluoperazine 1mg/5ml Syrup
2. Qualitative and quantitative composition
Each 5 ml dose contains 1 mg trifluoperazine present as the
hydrochloride.
3. Pharmaceutical form
A clear, pale yellow, peach flavoured syrup.
4. Clinical particulars
4.1 Therapeutic indications
Low dosage: 'Stelazine' is indicated as an adjunct in the short-term
management of anxiety states,
depressive symptoms secondary to anxiety and agitation. Orally it is
also indicated in the symptomatic
treatment of nausea and vomiting.
High dosage: 'Stelazine' is intended for the treatment of symptoms and
prevention of relapse in
schizophrenia and in other psychoses, especially of the paranoid type,
but not in depressive psychoses. It
may also be used as an adjunct in short-term management of severe
psychomotor agitation and of
dangerously impulsive behaviour in, for example, mental subnormality.
4.2 Posology and method of administration
DOSAGE:
ADULTS:
_Low dosage_: 2-4 mg a day given in divided doses, according to the
severity of the patient's condition. If
necessary, dosage may be increased to 6 mg a day, but above this level
extrapyramidal symptoms are
more likely to occur in some patients.
_High dosage_: The recommended starting dosage for physically fit
adults is 5 mg twice a day after a week
this may be increased to 15 mg a day. If necessary, further increases
of 5 mg may be made at three-day
intervals, but not more often. When satisfactory control has been
achieved, dosage should be reduced
gradually until an effective maintenance level has been established.
As with all major tranquillisers, clinical improvement may not be
evident for several weeks after starting
treatment, and there may be delay before recurrence of symptoms after
stopping treatment. Gradual
withdrawal from high dosage treatment is advisable.
CHILDREN
_Low dosage_: For children 3-5 ye